SCHEMBL10094352

SCHEMBL10094352

CC(C)c1ccccc1-c1cccc(C(=O)N(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.50
PDK2 Q15119 1/20 0.49
ERN1 O75460 5/20 0.47
BRD4 O60885 2/20 0.46
CECR2 Q9BXF3 3/20 0.45
BRD9 Q9H8M2 3/20 0.45
TRIM24 O15164 1/20 0.45
TAF1 P21675 1/20 0.45
SMARCA2 P51531 1/20 0.45
SMARCA4 P51532 1/20 0.45
BRPF1 P55201 1/20 0.45
EP300 Q09472 1/20 0.45
PBRM1 Q86U86 1/20 0.45
CREBBP Q92793 1/20 0.45
BAZ2B Q9UIF8 1/20 0.45
BAZ2A Q9UIF9 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FFAR1 O14842 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094443 0.83 KCNA5 (0.51) KCNA5PDK2ERN1BRD4CECR2
SCHEMBL26356060 0.83 AKR1C3 (0.47) BRD4CREBBPBAZ2BBAZ2AKMT2A
SCHEMBL10094322 0.83 KMO (0.56) KMT2AFFAR1LMNA
SCHEMBL10094392 0.82 KDM4E (0.50) KCNA5KMT2AFFAR1
SCHEMBL4068672 0.82 BAZ2B (0.51) PDK2BRD4CREBBPBAZ2BBAZ2A
SCHEMBL10094391 0.81 KCNA5 (0.41) KCNA5KMT2AMEN1FFAR1LMNA
SCHEMBL23479668 0.79 PDK2 (0.49) PDK2BRD4TAF1CREBBPKMT2A
SCHEMBL23479756 0.79 RAB9A (0.49) PDK2ERN1SMN1; SMN2FFAR1
SCHEMBL15723874 0.79 KCNA5 (0.53) KCNA5PDK2ERN1BRD4CECR2
SCHEMBL10094496 0.78 KCNA5 (0.52) KCNA5ERN1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885PDK2 1535/4885ERN1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.